IXICO plc Result of AGM (2251A)
17 Gennaio 2020 - 5:34PM
UK Regulatory
TIDMIXI
RNS Number : 2251A
IXICO plc
17 January 2020
17 January 2020
IXICO plc
("IXICO" or the "Company")
Results of AGM
IXICO plc (AIM: IXI), the AI data analytics company delivering
insights in neuroscience, can announce that resolutions one to five
were put forward to its Annual General Meeting held earlier today
and were duly passed whilst resolution six was not duly passed. The
votes cast at the meeting were as follows:
Resolution Description Total Votes % Votes Total Votes % Votes Withheld Votes
For Against cast
as a
% of
ISC
Reports and
1 Accounts 21,954,961 100.00% 200 0.00% 800 46.62
--------------------- ------------ -------- ------------ -------- --------- ------
2 Re-election
of Directors
--------------------- ------------ -------- ------------ -------- --------- ------
Re-election
2a of Giulio Cerroni 21,955,461 100.00% 500 0.00% 0 46.62
--------------------- ------------ -------- ------------ -------- --------- ------
Re-election
2b of Grant Nash 21,955,461 100.00% 500 0.00% 0 46.62
--------------------- ------------ -------- ------------ -------- --------- ------
Re-appointment
3 of Auditors 21,949,261 99.99% 1,700 0.01% 5,000 46.61
--------------------- ------------ -------- ------------ -------- --------- ------
Allotment of
4 Securities 21,953,961 99.99% 1,700 0.01% 300 46.62
--------------------- ------------ -------- ------------ -------- --------- ------
Disapply Pre-Emption
5 Provisions 21,953,761 99.99% 1,900 0.01% 300 46.62
--------------------- ------------ -------- ------------ -------- --------- ------
Amendment of
Rule 3 of the
Long-Term Incentive
6 Plan 10,641,004 48.48% 11,309,157 51.52% 5,800 46.61
--------------------- ------------ -------- ------------ -------- --------- ------
Charles Spicer, Chairman of the Board of IXICO, commented:
"The board notes the results of the resolution to approve the
amendment to the IXICO LTIP and, over the coming months, will
engage with those major shareholders who did not support this
resolution to understand their concerns."
For further information please contact:
IXICO plc +44 (0) 20 3763
Giulio Cerroni, Chief Executive Officer 7499
Grant Nash, Chief Financial Officer
Cenkos Securities PLC (Nominated adviser and sole broker)
Giles Balleny / Max Gould (Corporate Finance) +44 (0) 20 7397
Michael F Johnson / Russell Kerr (Sales) 8900
Optimum Strategic Communications
Mary Clark, Supriya Mathur, Manel Mateus +44 (0) 203 950
IXICO@optimumcomms.com 9144
About IXICO
IXICO's purpose is to advance medicine and human health by
turning data into clinically meaningful information, providing
valuable new insights in neuroscience and rare disease.
Our goal is to be a leading proponent in the use of Artificial
Intelligence (AI) in clinical development, to improve biopharma
R&D productivity through the adoption of breakthrough data
analytics in precision healthcare. Through the deployment of novel
AI algorithms, we analyse and interpret brain scans and digital
biosensor data to enable better trial design, patient selection and
ultimately clinical outcomes across all phases of clinical
evaluation. Our data analytics services are deployed on some of the
most important clinical trials in neuroscience, providing valuable
insights to disease progression and patient safety, enabling our
clients to make better informed decisions earlier in the clinical
development pathway.
More information is available on www.IXICO.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
RAGKKOBNABKDBDD
(END) Dow Jones Newswires
January 17, 2020 11:34 ET (16:34 GMT)
Grafico Azioni Ixico (LSE:IXI)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Ixico (LSE:IXI)
Storico
Da Apr 2023 a Apr 2024
